{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:51Z","timestamp":1790983011413,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Uncommon EGFR mutations account for approximately 10\u201315% of all EGFR-mutated non-small cell lung cancer (NSCLC), and the optimal management of unresectable stage III disease harboring isolated EGFR S768I mutations remains poorly defined. We report the case of a 55-year-old woman with unresectable stage IIIC lung adenocarcinoma harboring an isolated EGFR S768I mutation. Because platinum-based chemotherapy was discontinued owing to severe gastrointestinal toxicity, she received concurrent icotinib and definitive intensity-modulated radiotherapy (IMRT), achieving a partial response with a progression-free survival of approximately 8 months and only grade 1 oral mucositis. At disease progression, repeat biopsy followed by next-generation sequencing (NGS) identified an EGFR exon 20 insertion (p.V769_D770insSVV) together with a marked reduction in the abundance of the original EGFR S768I mutation. As comprehensive baseline genomic profiling was unavailable, these findings should be interpreted cautiously and may represent either treatment-associated molecular alteration or expansion of a pre-existing low-frequency resistant subclone rather than definitive acquisition of a new mutation. Subsequent treatment with afatinib, ivonescimab plus chemotherapy, and sunvozertinib was selected according to dynamic molecular profiling. This case suggests that concurrent icotinib and definitive radiotherapy may represent a feasible individualized treatment option for carefully selected patients with unresectable stage III EGFR-mutant NSCLC who are unable to tolerate standard concurrent chemoradiotherapy. More importantly, it highlights the value of repeat biopsy and comprehensive genomic profiling for interpreting molecular changes at disease progression and guiding subsequent individualized treatment in patients with uncommon EGFR mutations. However, these observations are derived from a single case and require validation in larger prospective studies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1902085","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:51:49Z","timestamp":1785905509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent icotinib and definitive radiotherapy followed by detection of an EGFR exon 20 insertion at disease progression in unresectable stage III EGFR S768I-mutant lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Bingyue","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Precision Radiation Oncology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchenxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Precision Radiation Oncology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Precision Radiation Oncology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Precision Radiation Oncology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Precision Radiation Oncology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.05.007","article-title":"S768I mutation in EGFR in patients with lung cancer","volume":"11","author":"Leventakos","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non\u2013small cell lung cancer treated with epidermal growth factor receptor\u2013tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051266","article-title":"Utility of next-generation sequencing in the reconstruction of clonal architecture in a patient with an EGFR mutated advanced non-small cell lung cancer: a case report","volume":"12","author":"Simarro","year":"2022","journal-title":"Diagnostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"B10","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100559","article-title":"Pneumonitis in patients receiving thoracic radiotherapy and osimertinib: a multi-institutional study","volume":"4","author":"Banla","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2016.79.4.248","article-title":"Mechanisms of epidermal growth factor receptor tyrosine kinase inhibitor resistance and strategies to overcome resistance in lung adenocarcinoma","volume":"79","author":"Chang","year":"2016","journal-title":"Tuberc Respir Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04033-x","article-title":"All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations","volume":"149","author":"Ullas","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115917","article-title":"Targeted therapies for EGFR exon 20 insertion mutation in non-small-cell lung cancer","volume":"25","author":"Seo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2024","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","author":"Sequist","year":"","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","author":"Riely","year":"","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1317","article-title":"1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study","volume":"35","author":"Doucet","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902085\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:52:05Z","timestamp":1785905525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902085\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1902085"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1902085","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1902085"}}